Compare BKSY & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BKSY | TBPH |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | United States | United States |
| Employees | 340 | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 726.7M | 824.9M |
| IPO Year | N/A | 2013 |
| Metric | BKSY | TBPH |
|---|---|---|
| Price | $34.05 | $16.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $28.50 | $18.40 |
| AVG Volume (30 Days) | ★ 2.0M | 510.5K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 279.13 |
| EPS | N/A | ★ 2.06 |
| Revenue | N/A | ★ $15,386,000.00 |
| Revenue This Year | $26.22 | $1.04 |
| Revenue Next Year | $29.28 | N/A |
| P/E Ratio | ★ N/A | $8.03 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.44 | $8.32 |
| 52 Week High | $36.34 | $21.03 |
| Indicator | BKSY | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 65.92 | 56.03 |
| Support Level | $16.87 | $13.41 |
| Resistance Level | N/A | $19.04 |
| Average True Range (ATR) | 3.59 | 0.51 |
| MACD | 0.77 | 0.30 |
| Stochastic Oscillator | 84.13 | 74.59 |
BlackSky Technology Inc is a provider of real-time geospatial intelligence. The company delivers on-demand, high-frequency imagery, monitoring, and analytics of some of the critical and strategic locations, economic assets, and events in the world. It designs, owns, and operates one of the industry's low earth orbit (LEO) small satellite constellations, optimized to capture imagery cost-efficiently where and when its customers need it. its Spectra AI software platform processes data from BlackSky's constellation and other third-party sensors to develop the critical insights and analytics that provide its customers with the actionable intelligence. Geographically, the company operates in North America, the Middle East, Asia, and Others.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.